Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity.

AIM To assess the effects of a novel type 1 insulin-like growth factor receptor (IGF-1R) inhibitor, NVP-AEW541, on cell proliferation and signal transduction of esophageal cancer. MATERIALS AND METHODS Cell proliferation assay and western blot were conducted to assess the antitumor effects of NVP-AEW541. Genetic modification of RAS by expression vector was applied for overexpression of mutant RAS. RESULTS More than 2 μmol/l of NVP-AEW541 was required to effectively inhibit the proliferation of esophageal cancer. NVP-AEW541 potently blocked the activation of IGF-1R and protein kinase B (PKB, also known as AKT), but not of mitogen-activated protein kinase kinase (MEK) and extracellular-signal-regulated kinases (ERK). Active RAS was not reduced by NVP-AEW541 in esophageal cancer cells TE-1, suggesting that insensitivity of esophageal cancer to NVP-AEW541 is due to the maintained RAS-MAPK activity, which did not arise from RAS mutation. Moreover, the transduction of mutant RAS reduced the sensitivity of TE-1 cells to NVP-AEW541. CONCLUSION Stimulation of RAS-MAPK pathway is associated with resistance to NVP-AEW541 in esophageal cancer. Combining NVP-AEW541 with inhibitors/antibodies against RAS-MAPK signaling molecules might be more effective for use against esophageal cancer.

[1]  L. Mazzucchelli,et al.  KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors , 2012, Clinical Cancer Research.

[2]  L. Abrahmsén,et al.  Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule 111In-DOTA-ZIGF1R:4551 , 2012, The Journal of Nuclear Medicine.

[3]  D. Reinke,et al.  R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[5]  Jeff S. Jasper,et al.  The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. , 2011, Cancer cell.

[6]  S. Trudel,et al.  Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134 , 2011, Clinical Cancer Research.

[7]  Laurence Doyle,et al.  Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures , 2011, PloS one.

[8]  Jingwu Xie,et al.  Identification of Signature Genes for Detecting Hedgehog Pathway Activation in Esophageal Cancer , 2011, Pathology & Oncology Research.

[9]  R. Maki.  Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Fargnoli,et al.  Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. , 2010, Cancer research.

[11]  Silvio Parodi,et al.  Ras-induced resistance to lapatinib is overcome by MEK inhibition. , 2010, Current cancer drug targets.

[12]  Jaw-Yuan Wang,et al.  Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab , 2010, Annals of surgery.

[13]  M. Wiedmann,et al.  Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. , 2010, World journal of gastroenterology.

[14]  R C Roovers,et al.  Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. , 2009, Current cancer drug targets.

[15]  Rongshi Li,et al.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. , 2009, Journal of medicinal chemistry.

[16]  M. Fukuoka,et al.  Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells , 2009, Clinical Cancer Research.

[17]  J. Gaedcke,et al.  Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis , 2009, Molecular Cancer Therapeutics.

[18]  O. Stoeltzing,et al.  Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. , 2008, European journal of cancer.

[19]  D. Flieder,et al.  Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors , 2008, Proceedings of the National Academy of Sciences.

[20]  Zeguang Han,et al.  siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells , 2008, Journal of Cancer Research and Clinical Oncology.

[21]  M. Miura,et al.  Overexpression of IGF-I receptor in HeLa cells enhances in vivo radioresponse. , 2007, Biochemical and biophysical research communications.

[22]  J. Cline,et al.  RasGRP1 overexpression in the epidermis of transgenic mice contributes to tumor progression during multistage skin carcinogenesis. , 2007, Cancer research.

[23]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[24]  Silvia Benvenuti,et al.  Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.

[25]  D. Carbone,et al.  Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. , 2006, Carcinogenesis.

[26]  D. Schuppan,et al.  Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. , 2006, Biochemical pharmacology.

[27]  M. Höpfner,et al.  The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. , 2006, Endocrine-related cancer.

[28]  D. Yee,et al.  Type I insulin-like growth factor receptor as a therapeutic target in cancer. , 2005, Cancer research.

[29]  N. Taira,et al.  Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. , 2005, Cancer letters.

[30]  D. Fabbro,et al.  In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. , 2004, Cancer cell.

[31]  M. Vieth,et al.  Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma , 2004, Oncogene.

[32]  D. Carbone,et al.  Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. , 2003, Cancer research.

[33]  G. Johnson,et al.  Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases , 2002, Science.

[34]  D. Carbone,et al.  Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. , 2002, Gastroenterology.

[35]  Z. Halpern,et al.  Activation of c-K-ras mutations in human gastrointestinal tumors. , 2000, Gastroenterology.

[36]  W. Kabsch,et al.  The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. , 1997, Science.

[37]  Xia Han,et al.  The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. , 2009, Cancer research.

[38]  H. Modjtahedi,et al.  Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. , 2008, International journal of oncology.

[39]  Ronald Rosenfeld,et al.  The IGF System , 1999, Contemporary Endocrinology.